Gene-modified T cell therapy.

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• Immune checkpoint inhibitor (ICI) therapy has revolutionized cancer treatment, achieving success in a subset of patients with progressive cancers.
• However, ICI efficacy is limited to 10-30% across many cancer types, highlighting the critical need for alternative strategies for resistant patient populations.
• Lack of tumor-specific lymphocyte induction is a likely reason for non-response to ICIs.

Purpose of the Study:

• To review the clinical progress of gene-modified T cell therapy for cancer treatment.
• To discuss the challenges and future directions for improving gene-modified T cell therapy, particularly for patients resistant to immune checkpoint inhibitors.

Main Methods:

• This review summarizes recent clinical developments in adoptive cell therapy.
• Focuses on gene-modified T cell therapies, including CAR T-cell therapy and TCR-engineered T-cell therapy.
• Discusses strategies to overcome resistance to immune checkpoint inhibitors.

Main Results:

• Gene-modified T cell therapy, including CAR T-cell and TCR-engineered T-cell therapies, shows promise in early clinical trials for various cancers.
• These therapies aim to enhance anti-tumor immunity by equipping T cells with specific tumor-targeting capabilities.
• The review highlights ongoing research to optimize T cell function and persistence for improved patient outcomes.

Conclusions:

• Adoptive cell therapy with gene-modified T cells represents a promising therapeutic avenue for patients with progressive cancers who are resistant to immune checkpoint inhibitors.
• Further research and clinical development are necessary to address current limitations and optimize the efficacy and safety of these advanced cancer treatments.